TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
Triggering receptor expressed on myeloid cells 2 (TREM2) is a microglial receptor that recognizes changes in the lipid microenvironment, which may occur during amyloid β (Aβ) accumulation and neuronal degeneration in Alzheimer’s disease (AD). Rare TREM2 variants that affect TREM2 function lead to an increased risk of developing AD. In murine models of AD, TREM2 deficiency prevents microglial clustering around Aβ deposits. However, the origin of myeloid cells surrounding amyloid and the impact of TREM2 on Aβ accumulation are a matter of debate. Using parabiosis, we found that amyloid-associated myeloid cells derive from brain-resident microglia rather than from recruitment of peripheral blood monocytes. To determine the impact of TREM2 deficiency on Aβ accumulation, we examined Aβ plaques in the 5XFAD model of AD at the onset of Aβ-related pathology. At this early time point, Aβ accumulation was similar in TREM2-deficient and -sufficient 5XFAD mice. However, in the absence of TREM2, Aβ plaques were not fully enclosed by microglia; they were more diffuse, less dense, and were associated with significantly greater neuritic damage. Thus, TREM2 protects from AD by enabling microglia to surround and alter Aβ plaque structure, thereby limiting neuritic damage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“loss of TREM2 function in AD mouse models restricts the ability of microglia to surround Aβ plaques15,16, proliferate, and convert to DAM10,15,17, which in turn leads to more profound neuritic dystrophy18,19.”
From Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease (2020) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“which may represent dystrophic neurons that accumulate over time as a result of ineffective microglial control of AD pathology due to lack of Trem218,19.”
From Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease (2020) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the compaction of protofibrillary Aβ into a dense core plaque, which requires apoE and is promoted by TREM2 (Bales et al., 1997b, 1999; Bien-Ly et al., 2012; Wang et al., 2016; Yuan et al., 2016), could be a protective mechanism that limits neurotoxicity of amyloid deposits once they start to build up in the aging brain.”
From Microglia in Alzheimer’s disease (2018) · cites this paper as Wang et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trem2 deficiency induces dynamic changes but an eventual increase in plaque and neuritic pathology (Jay et al., 2017; Wang et al., 2015; Wang et al., 2016; Yuan et al., 2016).”
From Elevated TREM2 Gene Dosage Reprograms Microglia Responsivity and Ameliorates Pathological Phenotypes in Alzheimer’s Disease Models (2018) · cites this paper as Wang et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lack of TREM2 results in impaired plaque trimming, which leads to enlarged plaques with reduced compaction48,49.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [48]
Experimental — accuracy not yet measured
42 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898 · cited 4×
“Brains were isolated 3 h after injection and made into single-cell suspension as previously described (Heneka et al., 2013).”
BackgroundMethodInfluentialIdentification of a unique TGF-β–dependent molecular and functional signature in microglia
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3599 · Cited by 2,543 · cited 1×
“However, phenotypic markers of migroglia, such as low expression of CD45 and high expression of the P2Y(12) receptor, are altered upon microglial activation and therefore do not precisely discriminate microglia from monocytes (Butovsky et al., 2014).”
BackgroundTREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model
Wang, Y., Cella, M., Mallinson, K., Ulrich, J. D., Young, K. L., Robinette, M. L., Gilfillan, S., Krishnan, G. M., Sudhakar, S., Zinselmeyer, B. H., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.049 · Cited by 1,736 · cited 11×
“…response to Aβ deposits in all AD models, changes in Aβ burden develop more slowly; therefore, the discrepancies in Aβ accumulation may be a result of the varied timing of the analyses—8 mo in 5XFAD mice (Wang et al., 2015) and 3–4 mo in APP PS1-21 mice (Ulrich et al., 2014; Jay et al., 2015).”
BackgroundMethodResultInfluentialSelf-citationAlzheimer’s Disease: The Challenge of the Second Century
Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002369 · Cited by 1,424 · cited 1×
“Key pathological features of AD consist of the deposition of amyloid-β peptide (Aβ) and hyperphosphorylated tau aggregates that, together, are linked with synapse loss and neuronal cell death, as well as activation of microglia and astrocytes (Holtzman et al., 2011).”
BackgroundSelf-citationAlzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis
Karch, C. M., & Goate, A. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.006 · Cited by 1,357 · cited 1×
“Recent genome-wide association studies have identified rare variants of genes that encode immune receptors as risk factors (Guerreiro and Hardy, 2014; Karch and Goate, 2015).”
BackgroundMicroglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease
Prinz, M., & Priller, J. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3722 · Cited by 1,329 · cited 1×
“Given that brain-resident microglia are capable of self-renewal and expansion (Gomez Perdiguero et al., 2013; Greter and Merad, 2013; Prinz and Priller, 2014), we next sought to determine if microglia associated with plaques resulted from the proliferation of resident microglia.”
BackgroundTakahashi, K., Rochford, C. D. P., & Neumann, H. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041611 · Cited by 1,124 · cited 2×
“TREM2 signaling promotes survival, proliferation, phagocytosis, and secretion of cytokines and chemokines (Takahashi et al., 2005; Otero et al., 2009; Wang et al., 2015).”
BackgroundThe Genetics of Alzheimer's Disease
Bertram, L., & Tanzi, R. E. (2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-385883-2.00008-4 · Cited by 760
The genetics of Alzheimer disease
Tanzi, R. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006296 · Cited by 727 · cited 2×
“The origin of nonfamilial AD is less well understood and may depend on a combination of genetic and nongenetic risk factors (Tanzi, 2012).”
Background
Cited by
Items 601–700 of 838
Ms4a4a deficiency ameliorates plaque pathology in a mouse model of amyloid accumulation
Danhash, E., Verbeck, A. C., Western, D., Díaz‐Pacheco, A. S., Galasso, G., You, S., Huang, G., Starr, E., Miller, N., Nadarajah, C. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70580 · Cited by 8
“22,23,76,77 CD33 inhibits phagocytosis of A β 42 in vitro, and CD33 deficiency in a mouse model of amyloid accumulation results in reduced plaque burden and increased microglial recruitment to plaques.”
Self-citationTranscriptional regulation of disease-relevant microglial activation programs
McQuade, A., Mishra, R., Hagan, V., Liang, W., Colias, P. J., Castillo, V. C., Gonzalez, B., Lubin, J. P., Haage, V. C., Marshe, V. S., et al. (2026) · Neuron · doi:10.1016/j.neuron.2026.07.001 · Cited by 8
Synergistic potential of TREM2 agonists and exercise training in Alzheimer’s disease
Zhang, J., Schneider, B. A., Muguerza, E., Chung, E. K., & Hsu, C. G. (2026) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00124.2025 · Cited by 6
Haskell, A. K., Kulas, J. A., Carter, W., Javens‐Wolfe, J., Hinkel, R. D., Moussaif, M., Smiley, J. S., Lazaro, O., Robertson, S., Palkowitz, A. D., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71117 · Cited by 7
“We find that iMG robustly express TREM2 and that expression of both TREM2 and DAP12 can be increased by interleukin (IL) -4 treatment, though this does not enhance myelin phagocytosis, suggesting TREM2 levels are not a limiting factor in myelin uptake.”
Systematic analysis of TREM2 and its carcinogenesis in pancreatic cancer
Zheng, W., Yu, W., Hua, R., He, J., Wu, N., Tian, S., Huang, W., & Qin, L. (2024) · Translational Cancer Research · doi:10.21037/tcr-24-201 · Cited by 6
“TREM2 signaling induces changes in cellular phenotype and function in a variety of contexts that involve induction of phagocytosis (6) and lipid metabolism (7), promotion of cell survival (8) and counteracting inflammatory activation (9).”
Balak, C. D., Schlachetzki, J. C. M., Lana, A. J., West, E., Hong, C., DuGal, J., Zhou, Y., Li, B., Spann, N. J., Saisan, P. A., et al. (2026) · Immunity · doi:10.1016/j.immuni.2026.07.008 · Cited by 9
Swain, P. S., Panda, S., Pati, S., & Dehury, B. (2023) · Journal of Molecular Modeling · doi:10.1007/s00894-023-05770-7 · Cited by 6
“TREM2 acts as a neuroprotector by suppressing the amyloid beta diffusion with the regulation of microglial activation around amyloid plaques during the early and mid-term AD [8, 31, 32].”
BackgroundCheray, M., Stratoulias, V., Joseph, B., & Grabert, K. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00522 · Cited by 7
Sugar Utilization by Microglia in Alzheimer's Disease
Marino, K. M., Shippy, D. C., & Ulland, T. K. (2024) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2025.578552 · Cited by 5
Self-citationHou, K., An, Z., Xu, Y., Wang, J., Zhou, M., Liu, Y., Zhu, X., & Wei, J. (2026) · npj Parkinson s Disease · doi:10.1038/s41531-025-01247-x · Cited by 5
Stephenson, H. G., Betthauser, T. J., Jonaitis, E. M., Hulle, C. V., Kollmorgen, G., Quijano‐Rubio, C., Ewers, M., Denecke, J., Ulland, T. K., Chin, N. A., et al. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106468 · Cited by 5
Self-citationPath analysis of biomarkers for cognitive decline in early Parkinson’s disease
Gramotnev, D. K., Gramotnev, G., Gramotnev, A., & Summers, M. J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268379 · Cited by 6
Microglial Drivers of Alzheimer's Disease Pathology: An Evolution of Diverse Participating States
Kuhn, M. K., & Proctor, E. A. (2024) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26723 · Cited by 5
Torok, J., Maia, P. D., Anand, C., & Raj, A. (2025) · Communications Biology · doi:10.1038/s42003-025-07575-1 · Cited by 12
“Microglia and the broader process of neu-roin fl ammationarewidelyacknowledgedaspivotalmediatorsofboth τ and amyloid-β (A β ) pathophysiology 24 – 32 .”
Hiding in plain sight: Do recruited dendritic cells surround amyloid plaques in Alzheimer’s disease?
Nelson, R. B., Rose, K. N., Menniti, F. S., & Zorn, S. H. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116258 · Cited by 6
Hat die Alzheimer-Forschung versagt? Das Scheitern amyloidbasierter klinischer Studien
Haass, C., & Levin, J. (2019) · Der Nervenarzt · doi:10.1007/s00115-019-0751-1 · Cited by 5
TREM2 coding variants in Slovak Alzheimer's disease patients
Ďurmanová, V., Javor, J., Párnická, Z., Minárik, G., Ocenasova, A., Vašečková, B., Kiralyova, I., Šutovský, S., Petrovič, R., & Shawkatová, I. (2022) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2104105 · Cited by 5
“TREM2 can also increase microglial cell number, proliferation, and survival resulting in clustering of microglia to amyloid plaques [27,32,33].”
BackgroundRikos, D., Siokas, V., Mentis, A. A., Aloizou, A., Liampas, I., Tsouris, Z., Peristeri, E., Stamati, P., Hadjigeorgiou, G. M., & Dardiotis, E. (2022) · International Journal of Neuroscience · doi:10.1080/00207454.2022.2150844 · Cited by 15
“Additionally, microglia possesses the capability of phagocytosing plaque components, an ability which is also impaired upon TREM2 deficiency [ 60 ].”
BackgroundThe Amyloid-beta rich CNS environment alters myeloid cell functionality independent of their origin
Drost, N., Houtman, J., Cseresnyés, Z., Niesner, R. A., Rinnenthal, J.-L., Miller, K. R., Prokop, S., & Heppner, F. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-63989-3 · Cited by 5
Zhang, G., Xia, S., Zhang, N. K., Gao, F., Zloković, B. V., Zhang, L. I., Zhao, Z., & Tao, H. W. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.07.539389 · Cited by 5
“…al. 2018; Marta Olah et al. 2020; Blue B. Lake et al. 2016; Jorge L. Del-Aguila et al. 2019), as well as in animal models such as the 5xFAD (Yaming Wang et al. 2016; Habib et al. 2020; Minghui Wang et al. 2022) and APP/PS1 mice (Minghui Wang et al. 2022; Emma Gerrits et al. 2021; Soyon Hong et…”
Luikku, A. J., Nerg, O., Koivisto, A. M., Hänninen, T., Junkkari, A., Kemppainen, S., Juopperi, S.-P., Sinisalo, R., Pesola, A., Soininen, H., et al. (2024) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlae083 · Cited by 5
Targeting mitochondrial dysfunction: Innovative strategies to combat glaucoma neuroinflammation
Lu, W. B., Liao, Z., Jiang, X., Deng, Q., Deng, Q., Zhou, X., Lü, M., & Duan, X. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110441 · Cited by 4
Chen, H., Cao, J., Zhang, Y., Su, X., Kang, Y., Gao, L., & Jing, Y. (2025) · The FASEB Journal · doi:10.1096/fj.202501545rr · Cited by 4
“Synapses are essential structures involved in neurotransmission and neuroplasticity, and their activity relies on structural and functional integrity that supports learning, memory, and cognitive function [1].”
He, S., Mittra, N., Bao, H., Bhattacharjee, A., Dodds, S. G., Dupree, J. L., & Han, X. (2026) · Nature Communications · doi:10.1038/s41467-025-66222-9 · Cited by 4
“In addition to neuroin fl ammation, TREM2 also mediates the induction of phagocytic pathways and regulates lipid metabolism 10,30,33,35 .”
Looking at the periphery—new hypothesis to look for new targets for Alzheimer’s disease therapy
Ávila, J., Pérez, M., Ávila‐Villanueva, M., Santa‐María, I., & Hernández, F. (2023) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2023.00044 · Cited by 4
Mitigation of CXCL10 secretion by metabolic disorder drugs in microglial-mediated neuroinflammation
Oliai, S. F., Shippy, D. C., & Ulland, T. K. (2024) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2024.578364 · Cited by 5
Self-citationNeuroimmune Dysfunction in Alzheimer’s Disease and Other Forms of Dementia
Yamane, T., Yoshioka, T., & Shimo, Y. (2024) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c23-00464 · Cited by 5
Generation of an Inducible Destabilized‐Domain Cre Mouse Line to Target Disease Associated Microglia
Henningfield, C. M., Ngo, M., Murray, K. M., Kwang, N. E., Tsourmas, K. I., Neumann, J. C., Pashkutz, Z. A., Kawauchi, S., Swarup, V., Lane, T. E., et al. (2025) · Glia · doi:10.1002/glia.70004 · Cited by 4
“…TREM2 mediates the microglial response to plaques, as shown by its knockout in models of amyloidosis (Keren-Shaul et al. 2017; Jay et al. 2015; Wang et al. 2016), but loss of TREM2 function also causes perturbations in homeostatic microglial function leading to the neurodegenerative disease…”
Pregabalin Treatment does not Affect Amyloid Pathology in 5XFAD Mice
Sadleir, K. R., Popovoic, J., Zhu, W., Reidel, C. T., Do, H., Silverman, R. B., & Vassar, R. J. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666210713125333 · Cited by 4
“In mice with either the deletion of or the introduction of AD-associated mutations in the AD risk gene TREM2, microglia failed to migrate to and wall-off plaques, which were less compacted and had a higher degree of neuritic dystrophy [73, 74].”
Toledano‐Díaz, A., Álvarez, M. I., & Tolédano, A. (2022) · Journal of Central Nervous System Disease · doi:10.1177/11795735221123896 · Cited by 5
“(a) Common polymorphisms in the apolipoprotein E (APOE) gene are the major genetic determinants for AD: APOE4 is the strongest genetic risk factor of Late-onset Alzheimer’s disease risk.19 Brain apoE is mainly produced by astrocytes and to a lesser extent by microglia, oligodendrocytes, vascular mural cells, and neuro…”
BackgroundInfluentialGreven, J. A., Osario, O., Nix, J. C., Alexander‐Brett, J. M., & Brett, T. J. (2024) · SSRN Electronic Journal · doi:10.1101/2024.05.23.595586 · Cited by 5
“In microglia, binding of Aβ to TREM2 induces downstream signaling for microglia activation and phagocytosis which are beneficial to remove oAβ and regulate Aβ plaque formation [9].”
BackgroundFueling Alzheimer’s Disease: Where Does Immunometabolism Stand?
Correia, S. C., Perry, G. L., & Moreira, P. I. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240787 · Cited by 3
“34 , 129 , 169 Studies addressing the role of the dynamic aspect of mitochondrial biology during chronic activation of brain-resident immune cells in AD are scarce.”
Andreo‐Lopez, J., Nuñez‐Diaz, C., Huynh, K. D., Nguyen, M. M. T., Cunha, C. D., Cantero‐Molina, F., Campos‐Moreno, C., Zimbone, S., Bellia, F., Giuffrida, M. L., et al. (2025) · Aging Cell · doi:10.1111/acel.70094 · Cited by 3
“In addition, recent evidence suggests that microglia take part in several pathogenic processes, such as amyloid and tau propagation, aggregation, plaque compaction, as well as protection against dystrophic neurites (Condello et al. 2015; Tran et al. 2023; Y. Wang et al. 2016).”
InfluentialThe Interaction between Oligodendrocytes and Aβ in Alzheimer's Disease
Wang, W., Huang, X., Xu, Z., & Yu, C. (2025) · Current Alzheimer Research · doi:10.2174/0115672050401966250625171338 · Cited by 3
“Under conditions of decreased Aβ, they migrate toward lesion sites and increase their phagocytic activity, thereby facilitating enhanced Aβ clearance [114, 115].”
Unmasking early microglial remodeling in an Alzheimer’s disease mouse model
Saminathan, P., McArdle, S., Corey, M., Nadig, N., Fang, C., Gibbons, A., Rayadurgam, M., & Sharma, S. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1720382 · Cited by 3
“Microglia accelerate rapid plaque compaction and form barrier-like assemblies that limit amyloid spread and neuritic dystrophy, suggesting a context dependent balance between containment and collateral damage 18,20,21 .”
Yang, N., Jiang, J., Shi, J., Liu, X., Yu, C., Guo, S., Zhang, C., Gao, F., Yang, Z., Feng, H., et al. (2026) · Inflammation · doi:10.1007/s10753-025-02435-w · Cited by 4
“As the disease progresses, TREM2 expression increases, exhibiting stage-dependent effects that can exacerbate neuroinflammation in later stages while concomitantly promoting Aβ clearance and reducing inflammation, thereby providing neuroprotection in the early stages [15–17].”
TREM2 as a possible link between Alzheimer's disease and diabetes mellitus
Chen, W., Huang, N., Huang, W., Wang, M., Luo, Y., & Huang, J. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.115739 · Cited by 3
Type-1 interferons associated with microglial-mediated neuroinflammation in Alzheimer’s disease
Shippy, D. C., Sande, M. L., & Ulland, T. K. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03828-w · Cited by 4
“Aβ: amyloid-β; AD: Alzheimer’s disease; IRM: interferon-responsive microglia; ISGs: interferon-stimulated genes; NA + : nucleic acid-containing; NFTs: neurofibrillary tangles fitness and clearance of Aβ plaques [14, 15, 131–136].”
Self-citationMicroglial Plasticity in Vascular Dementia: Mechanisms and Therapeutic Reprogramming
Shukla, M., Li, J., Sun, Y., Jin, R., & Li, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093719 · Cited by 3
“For example, activation of TREM2 enhances microglial phagocytic capacity, promotes debris clearance, and limits excessive pro-inflammatory cytokine production in models of neurodegenerative diseases, with reported improvements in cognitive outcomes [82,83].”
Ma, J., Yang, B., Jiang, X., Wang, L., Wei, W., Cao, Y., & Li, H. (2026) · Experimental Gerontology · doi:10.1016/j.exger.2026.113177 · Cited by 4
Li, Y., Lei, Z., Ritzel, R. M., He, J., Liu, S., Zhang, L., & Wu, J. (2024) · Cells · doi:10.3390/cells13181584 · Cited by 3
Zelada, D., Saldivia, N., Samano, S., George, D., Chaudhari, K., Nguyen, D. A., Simchuk, D., van Breemen, R. B., & Givogri, M. I. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s523938 · Cited by 3
TREM2 and APOE are dispensable for microglial clearance of dying neurons revealed by in vivo imaging
Rai, A., Damisah, E. C., Hill, R., Tong, L., & Grutzendler, J. (2025) · iScience · doi:10.1016/j.isci.2025.114559 · Cited by 3
Self-citationYuan, Q., Liu, X., Zhang, Y., Xian, Y., Zou, J., Zhang, X., Huang, P., Song, Y., & Lin, Z. (2021) · Molecules · doi:10.3390/molecules26092685 · Cited by 3
“Different outcomes including augments [10,11], no effects [12,13], and even reductions of extracellular plaque pathology were reported in TREM2-deficient mice [14].”
BackgroundHow Many Alzheimer–Perusini’s Atypical Forms Do We Still Have to Discover?
Donato, L., Mordà, D., Scimone, C., Alibrandi, S., D’Angelo, R., & Sidoti, A. (2023) · Biomedicines · doi:10.3390/biomedicines11072035 · Cited by 3
Ojo, J. O., Leary, P., Lungmus, C., Algamal, M., Mouzon, B., Bachmeier, C. J., MULLAN, M. J., Stewart, W. B., Jr., & Crawford, F. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly101 · Cited by 3
Sayed, F. A., Kodama, L., Udeochu, J. C., Fan, L., Carling, G. K., Le, D., Li, Q., Zhou, L., Mathys, H., Wang, M., et al. (2020) · doi:10.1101/2020.07.24.218719 · Cited by 3
Translational control of microglial inflammatory and neurodegenerative responsesPreprint
Bermudez, S., Choi, J., Vogel, J. W., Kim, S., Mahmood, N., Zhu, V. Y., Cozachenco, D., Yaqubi, M., Zhou, L., Stratton, J. A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.06.587750 · Cited by 3
“Although ample evidence supports a role for both the neuroprotective role of microglia in AD and its ultimate loss, microglia functions depend on complex intracellular signaling pathways and the precise molecular pathways that underly these processes are not completely understood (9, 14-16).”
BackgroundLiu, Z., Hu, B., Tang, J., Liu, X., Cheng, B., Jia, C., & Zhang, L. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241289381 · Cited by 2
Xu, Y., Wu, T., Lo, L. T., Ko, C., Wang, X., & Ma, C. H. E. (2025) · Advanced Science · doi:10.1002/advs.202505421 · Cited by 2
Burdman, G., Akkaoui, J., Colon, N., Perez, A. G., & Lakshmana, M. K. (2026) · Neurology International · doi:10.3390/neurolint18030050 · Cited by 2
“Thus, TREM2 contributes to resilience when activation thresholds are optimized to support clearance and containment without triggering chronic neuroin-flammation [72,73].”
Gateways for myeloid cell entry into the central nervous system
Amann, L., & Prinz, M. (2026) · Neuron · doi:10.1016/j.neuron.2026.04.001 · Cited by 2
Mikołajczak, K., Chmiel, J., & Leszek, J. (2026) · Cells · doi:10.3390/cells15121111 · Cited by 2
“TREM2, a microglial receptor essential for phagocytosis and survival, is upregulated around AD plaques [216–218] and also expressed by TAMs in glioblastoma (though its role in glioblastoma is less clear—interestingly, TREM2 + macrophages have been noted in some cancers as an immunosuppressive…”
Impact of sex differences on microglial function in Alzheimer’s disease
Figueiredo, E. V., Azevedo, C. V., Penitente, A. R., Pedrosa, V. R., da Silva, V. R. C., & Longo, B. M. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02099-0 · Cited by 3
“In doing so, microglia adopt diverse context-dependent states that can be protective (e.g., containment and clearance programs) [8, 16] or potentially detrimental when dysregulated (e.g., sustained cytokine signaling [17], excessive reactivation of complement-driven synapse pruning [18], and…”
Li, M., Song, Q., Jie, S., Wang, C., Zhang, C., Chi, K., Gao, Y., & Li, T. (2025) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70008 · Cited by 2
“It is important in mediating microglial metabolic fitness through the stress events, enabling cellular progression to the totally mature DAM profiles and finally maintaining microglial response to protein Aβ plaque-caused pathology [59, 60].”
Romero‐Molina, C., Neuner, S. M., Ryszawiec, M., Pébay, A., Dominantly Inherited Alzheimer Network, Marcora, E. M., & Goate, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052565 · Cited by 5
Emerging Microglial Therapies and Targets in Clinical Trial
Yan, L., & Crotti, A. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-55529-9_35 · Cited by 3
Apolipoprotein E (APOE) Isoforms and Neurobiology of Sporadic Alzheimer’s Disease
Mollica, A., Berardino, G., Bellomo, A., Altamura, M., Panza, F., & Lozupone, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-32035-4_155-1 · Cited by 2
Liu, C., Wang, X., Xu, W., Yu, S., Zhang, Y., Xu, Q., & Tan, X. (2025) · Pharmaceuticals · doi:10.3390/ph18070977 · Cited by 2
Impaired Efferocytosis of Pericytes and Vascular Smooth Muscle Cells in Diabetic Retinopathy
Gardiner, T. A., Little, K., & Stitt, A. W. (2025) · Cells · doi:10.3390/cells14171349 · Cited by 2
“In AD, dysfunction of TREM2 impairs the compaction and removal of amyloid plaques [78,79], consistent with its function as a receptor for amyloid beta [80].”
Cell composition at the vitreomacular interface in traumatic macular holes
Guenther, S. R., Schumann, R. G., Zaytseva, Y., Hagenau, F., Wolf, A., Priglinger, S. G., & Vogt, D. (2021) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-021-05470-z · Cited by 2
He, M., Lian, T., Guo, P. F., Zhang, W., Zhang, Y., Huang, Y. M., Liu, G., Guan, H., Li, J., Luo, D., et al. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14440 · Cited by 2
Fan, Y., Yang, Y., Lin, K., Zhou, X., Li, Y., & Lin, Q. (2023) · Open Medicine · doi:10.1515/med-2023-0800 · Cited by 2
The γ-Secretase Protease Complexes in Neurodegeneration, Cancer and Immunity
Coleman-Vaughan, C., Mal, A., De, A., & McCarthy, J. V. (2017) · Springer eBooks · doi:10.1007/978-981-10-6141-7_3 · Cited by 4
Kemal, S., & Vassar, R. J. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20191536 · Cited by 3
“Some studies have pointed to the beneficial role of microglia in compacting Aβ plaques and protecting neurites against damage (Condello et al., 2015; Wang et al., 2016; Yuan et al., 2016).”
BackgroundSex differences in microglia as a risk factor for Alzheimer’s disease
Delage, C. I., Rendina, D. N., Malacon, K. E., Tremblay, M., & Bilbo, S. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819344-0.00008-9 · Cited by 3
Blank-Stein, N., Mayer, M., & Mass, E. (2021) · Advances in immunology · doi:10.1016/bs.ai.2021.08.001 · Cited by 4
Chronic PPARγ Stimulation Shifts Amyloidosis to Higher Fibrillarity but Improves CognitionPreprint
Blume, T., Deußing, M., Biechele, G., Peters, F., Zott, B., Schmidt, C., Franzmeier, N., Wind-Mark, K., Eckenweber, F., Sacher, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.30.446348 · Cited by 3
Self-citationRosene, M. J., Hsu, S., You, S. F., Brase, L., Verbeck, A. C., Martinez, R. J., Wallace, C. E., Li, Z., Yan, P., Dräger, N. M., et al. (2022) · medRxiv · doi:10.1101/2022.01.31.22270175 · Cited by 2
Self-citationHuman IL-34 Deficiency Primes Microglia Toward Alzheimer’s Disease-Associated StatesPreprint
Hernández-Rasco, F., Ruiz, R. R., de Rojas, I., Puerta, R., Garcia-Mayor, C., Espinosa‐Oliva, A. M., García‐Revilla, J., Bayón-Buján, P., Rivera-Ramos, A., Oualit, F. R., et al. (2026) · medRxiv · doi:10.64898/2026.02.21.26346696 · Cited by 3
Song, M., Liu, R., Zhang, L., Liu, C., Song, F., & Zhao, X. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117551 · Cited by 1
Myers, S. J., Medapati, M. R., Allman, B. L., Pasternak, S., Whitehead, S. N., & Roseborough, A. D. (2026) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2026.101261 · Cited by 1
“However, the effect of TREM2 deficiency on AD pathology is inconsistent across studies, varying by brain region, age, and model (Ulrich et al., 2014; Jay et al., 2015, 2017; Wang et al., 2016a, 2016b).”
Visualising the Knowledge Structure of Microglia in Alzheimer’s Disease: A CiteSpace Analysis
Wang, Q., Zhang, X. C., Wang, D., Jiang, X., Zhou, Y., Zhang, T., Yang, X., Liu, L.-Z., & Li, Q. (2025) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s521350 · Cited by 1
“The “diversification” stage saw the emergence of hotspots such as TREM2 mutation, Tau protein pathology and NLRP3 inflammasome; highly cited papers such as Keren-Shaul, 47 Liddelow, 37 and Wang 24 laid a new framework for immune imbalance and synaptic damage.”
Zhao, P., Fadel, O. E., Le, A., Mangleburg, C. G., Dhindsa, J. S., Wu, T., Zhao, J., Huang, M., Amoh, B. K., Marella, A. S., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03479-6 · Cited by 2
“Importantly, genetic manipulations of immune regulators such as TREM2 or NFkB in microglia have also been demonstrated to modify neurodegeneration, supporting causal roles for these pathways [20, 21].”
Chimal‐Juárez, E., Jury, N., Gómez-Isaza, L., Troncoso, J. C., & Lasagna‐Reeves, C. A. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71208 · Cited by 3
“98 TREM2regulatesmicroglialactivationandA β structure 99,100 ;whereas its activation can reduce plaque burden, 101,102 chronic stimulation may be detrimental.”
Hirota, Y., Yamamoto, J., Takatori, S., Sakakibara, Y., Takei, K., 佐治多美子, Sekiya, M., Tomita, T., & Iijima, K. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00032-1 · Cited by 1
“Tau phosphorylated at serine 202 and threonine 205 sites (p-tau202/205; AT8) has been used as a marker of neuritic plaques, which are believed to represent dystrophic neurites surrounding Aβ plaques [102, 103].”
Microglial ITAM & ITIM Signaling in Neurodegenerative Disease and Brain Aging
Mangalmurti, A., Bonheur, A., & Lukens, J. R. (2026) · Journal of Molecular Biology · doi:10.1016/j.jmb.2026.169910 · Cited by 2
Human Microglial Molecular Alterations in Aging and Alzheimer’s Disease
Baldo, K. A. T., Gozlan, E., Chidebe, E. O., Awogbindin, I. O., Prieto, M. O., Dalmacio, L. M. M., Ben-Azu, B., Frenkel, D., & Tremblay, M. (2026) · Cells · doi:10.3390/cells15131159 · Cited by 1
“…although some components of the plaque-associated microglia state, including a strong upregulation of CD11c/lipid-lysosomal pathways, are blunted in the absence of TREM2, consistent with the involvement of the TREM2-TYROBP axis in the maintenance of disease-associated microglia [36,158,159,163].”
Saravanan, J., Easwaran, V., Selvaraj, D., Gunasekaran, V., Soumya, V., Thiruselvi, M., Prasanth, M. L., Singh, S., Ellaiyarasu, C., Rai, P. K., et al. (2026) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2026.104108 · Cited by 1
Tung, T.-H., Babu, S., Tang, X., Sciutto, A. L., Romer, M. A., Racha, P., 徐, R. 榕. X., Fiesler, V. M., Saha, A., Thai, T., et al. (2026) · Brain · doi:10.1093/brain/awag234 · Cited by 1
Dejanovic, B., Figley, M. D., Weisman, E. F., Kiragasi, B., Gergits, F. W., Larson, K., Renoux, A. J., Rajagovindan, R., Pandya, B. A., Houze, J. B., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aec5740 · Cited by 2
Self-citationImmune Senescence and Inflammaging in Neurological Diseases
Baden, P., Cicco, S. D., Yu, C., & Deleidi, M. (2019) · Springer eBooks · doi:10.1007/978-3-319-99375-1_143 · Cited by 1
Contribution of “Genuine Microglia” to Alzheimer's Disease Pathology
Hashioka, S., Inoue, K., Otsuki, K., Hayashida, M., Wake, R., Kawano, N., Takeshita, H., & Inagaki, M. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.815307 · Cited by 1
Pang, Y., Zhu, S., Xu, J., Su, C., Wu, B. Y., Zhang, C., & Gao, J. (2023) · Advanced Biology · doi:10.1002/adbi.202200321 · Cited by 4
Guffart, E., & Prinz, M. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-55529-9_3 · Cited by 1
Achouri-Rassas, A., Fray, S., Saied, Z., Sassi, S. B., Ali, N., & Baraket, G. (2025) · Neurological Research · doi:10.1080/01616412.2025.2472841 · Cited by 1
“TREM2 is a single-pass transmembrane receptor that, when binding to the ligand, activates a series of downstream immune-related intracellular signalling cascades [23].”
Mild Cognitive Impairment and Early Dementia
Damasceno, B. P. (2020) · Springer eBooks · doi:10.1007/978-3-030-57267-9_20 · Cited by 1
Neuroinflammation in Alzheimer's Disease Continuum
Sag, A. T., & Yemişçi, M. (2020) · Neurological Sciences and Neurophysiology · doi:10.4103/nsn.nsn_190_20 · Cited by 1
Microglia and macrophages in central nervous systems
Cho, I. K. H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822368-0.00008-6 · Cited by 3
Carbajosa, G., Malki, K., Lawless, N., Wang, H., Ryder, J. W., Wozniak, E., Wood, K., Mein, C. A., Hodgkinson, A., Dobson, R., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.16.452732 · Cited by 1
“…and spread in dystrophic neurons surrounding amyloid-β plaques in familial models of AD (Ulrich et al., 2014; Jay et al., 2015; Wang et al., 2015; Wang et al., 2016; Yuan et al., 2016; Bemiller et al., 2017; Jay et al., 2017; Cheng-Hathaway et al., 2018; Sayed et al., 2018; Song et al., 2018;…”
BackgroundVrba, S. M., Laaker, C. J., Limkar, A. R., Hsu, M., Ricke, W. A., Ulland, T. K., Pehar, M., Sándor, M., & Fábry, Z. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.15.654007 · Cited by 1
Self-citationKikuchi, M., Miyashita, A., Hirota, Y., Hara, N., Hasegawa, M., Sakakibara, Y., Sekiya, M., Ozaki, K., Niida, S., Morishima, M., et al. (2025) · medRxiv · doi:10.1101/2025.10.06.25336925 · Cited by 1
Pattanashetty, S. G., Serrano, P. A., Rockwell, P., Xie, L., & Figueiredo-Pereira, M. E. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.02.716175 · Cited by 1
Lam, S. (2021) · theses.fr (ABES) · doi:10.70675/60b353ffz56fcz41a2z9e53zf0d9ac078167 · Cited by 1
Genetic Risk Factors for Complex Forms of Alzheimer’s Disease
Bellenguez, C., & Lambert, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-72938-1_4
Genetic manipulation of CNS cholesterol metabolism and its effects on cerebral β-amyloidosis
Winchenbach, J. (2019) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7274
Immunology of Alzheimer’s disease
Sosa-García, L. I., Hernández-Jiménez, J., Moral, D. I. D., Duyckaerts, C. J., & Calderón‐Garcidueñas, A. L. (2019) · Revista de Fomento Social · doi:10.24875/rmn.19000010
“In murine models of AD, the loss of TREM2 causes increased deposits of A β in the hippocampus due to a dysfunctional response of the microglia to A β suggesting that TREM2 facilitates the clearance of A β by these cells 24 .”
Investigation into the molecular complexity of Alzheimer's disease : an amyloid-β centered approach
Cioffi, F. (2019) · doi:10.3990/1.9789036548410 · Cited by 1
Koch, B. M. E. (2019) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7716
Perbandingan hukum perdata / oleh R. Soeroso
Soeroso, R. (1993) · Cited by 9
Metadata
- Authors
- Wang, Y., Ulland, T. K., Ulrich, J. D., Song, W., Tzaferis, J. A., Hole, J. T., Yuan, P., Mahan, T. E., Shi, Y., Gilfillan, S., Cella, M., Grutzendler, J., DeMattos, R. B., Cirrito, J. R., Holtzman, D. M., & Colonna, M.
- Affiliations
- Eli Lilly (United States) (US)
- Washington University in St. Louis (US)
- Yale University (US)
- Corresponding author
- Colonna, Marco
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2016-04-18
- Volume
- 213
- Issue
- 5
- Pages
- 667-675
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4854736
- OpenAlex
- W2339534121
- Cited by
- 840
- References
- 32
- Citations by year
- 2026: 62 · 2025: 76 · 2024: 86 · 2023: 106 · 2022: 114 · 2021: 102 · 2020: 93 · 2019: 73 · 2018: 61 · 2017: 50 · 2016: 16
- FWCI
- 36.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Funders
- Eli Lilly and Company
- National Institutes of Health (RF1 AG05148501, 5T32CA009547-30, AG047644)
- National Multiple Sclerosis Society (RG4687A1/1)
- Cure Alzheimer’s Fund
- JPB Foundation
- Knight Alzheimer’s Disease Research Center (P50 AG005681-30)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Keywords
- TREM2, microglia, amyloid plaques, Alzheimer's disease, parabiosis, 5xFAD mice, TREM2 deficiency, lipid microenvironment, peripheral blood monocytes
- MeSH terms
- Alzheimer Disease, Animals, Disease Models, Animal, Humans, Membrane Glycoproteins, Monocytes, Receptors, Immunologic, Amyloid beta-Peptides, Neurites, Microglia, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.